Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)

被引：0
|
作者：
O'Brien, Susan M. [1 ]
Jones, Jeffrey A. [2 ]
Furman, Richard R. [3 ]
Coutre, Steven E. [4 ]
Flinn, Ian W. [5 ]
Burger, Jan A. [1 ]
Blum, Kristie A. [2 ]
Sharman, Jeff P. [6 ]
Wierda, William G. [1 ]
Zhao, Weiqiang [2 ]
Heerema, Nyla A. [2 ]
Johnson, Amy J. [2 ]
Tran, Anh [7 ]
Zhou, Cathy [7 ]
Bilotti, Elizabeth [7 ]
James, Danelle F. [7 ]
Byrd, John C. [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[4] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Willamette Valley Canc Inst & Res Ctr, Springfield, OR USA
[7] Pharmacyclics Inc, Sunnyvale, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2015年 / 15卷
关键词：
D O I：
10.1016/j.clml.2015.04.068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
308
引用
收藏
页码：S206 / S206
页数：1
相关论文
共 50 条
  • [1] Integrated and Long-Term Safety Analysis of Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 13 - 14
  • [2] Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Coutre, Steven
    Byrd, John C.
    Hillmen, Peter
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Devereux, Stephen
    Robak, Tadeusz
    Kipps, Thomas J.
    Schuh, Anna
    Moreno, Carol
    Furman, Richard R.
    Burger, Jan
    O'Dwyer, Michael
    Ghia, Paolo
    Valentino, Rudolph
    Suzuki, Samuel
    Ninomoto, Joi
    James, Danelle F.
    O'Brien, Susan M.
    [J]. BLOOD, 2016, 128 (22)
  • [3] LONG-TERM FOLLOW-UP OF SINGLE-AGENT IBRUTINIB IN FIRST-LINE AND RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
    Reid, Mark
    Settlemire, Jillian
    Liu, Emily
    Amaya-Chanaga, Carlos
    Coutre, Steven
    Byrd, John
    [J]. ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [4] Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies
    Coutre, Steven E.
    Byrd, John C.
    Hillmen, Peter
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Devereux, Stephen
    Robak, Tadeusz
    Kipps, Thomas J.
    Schuh, Anna
    Moreno, Carol
    Furman, Richard R.
    Burger, Jan A.
    O'Dwyer, Michael
    Ghia, Paolo
    Valentino, Rudolph
    Chang, Stephen
    Dean, James P.
    James, Danelle F.
    O'Brien, Susan M.
    [J]. BLOOD ADVANCES, 2019, 3 (12) : 1799 - 1807
  • [5] LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA TREATED WITH FLUDARABINE AS A SINGLE-AGENT
    KEATING, MJ
    OBRIEN, S
    KANTARJIAN, H
    PLUNKETT, W
    ESTEY, E
    KOLLER, C
    BERAN, M
    FREIREICH, EJ
    [J]. BLOOD, 1993, 81 (11) : 2878 - 2884
  • [6] Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.
    Byrd, John C.
    Hillmen, Peter
    O'Brien, Susan Mary
    Barrientos, Jacqueline Claudia
    Reddy, Nishitha M.
    Coutre, Steven
    Tam, Constantine S.
    Mulligan, Stephen P.
    Jager, Ulrich
    Barr, Paul M.
    Furman, Richard R.
    Kipps, Thomas J.
    Thornton, Patrick
    Pagel, John M.
    Burger, Jan Andreas
    Jones, Jeffrey Alan
    Dai, Sandra
    Vezan, Remus N.
    James, Danelle Frances
    Brown, Jennifer R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia
    Hanna, Kirollos S.
    Fijalka, Andrew
    Watson, Ian
    Brown, Olivia
    Ojulu, Apiew
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1869 - 1884
  • [8] Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Jaglowski, Samantha M.
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Andritsos, Leslie A.
    Maddocks, Kami J.
    Woyach, Jennifer A.
    Blum, Kristie A.
    Greyer, Michael R.
    Geyer, Susan Michelle
    Heerema, Nyla A.
    Lozanski, Gerard
    Stefanos, Mona
    Hall, Nathan
    Nagar, Veena
    Munneke, Brian
    West, Jamie-Sue
    Neuenburg, Jutta K.
    James, Danelle F.
    Johnson, Amy J.
    Byrd, John C.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S206 - S207
  • [9] Real-World Outcomes of Patients Treated with Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Systematic Review and Meta-Analysis
    Cheung, Matthew C.
    Amitai, Irina
    [J]. BLOOD, 2020, 136
  • [10] Cladribine (CdA) therapy in chronic lymphocytic leukemia (CLL) - Long-term follow-up of 117 patients
    Juliusson, G
    Stromberg, M
    Liliemark, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 395 - 395
12345